Percutaneous transluminal septal myocardial ablation: a new catheter-based therapy for patients with hypertrophic
H M Farouque1, S G Worthley, R A Skyrme-Jones
1Centre for Heart and Chest Research, Monash Medical Centre and Monash University, Melbourne, Australia.
Abstract:
Hypertrophic obstructive cardiomyopathy is a complex disorder with serious clinical implications. Percutaneous transluminal septal myocardial ablation is a promising new addition to existing therapies for this condition. It is a catheter-based approach that involves instilling alcohol into the septal branches of the left anterior descending artery to induce a 'controlled' septal myocardial infarct. The result is a decrease in thickness of the hypertrophied interventricular septum and a reduction of the left ventricular outflow tract gradient. To date, the results from several series have been promising, with improvements in haemodynamic and clinical parameters without prohibitive complication rates. In this article, the indications, technique and outcomes of this procedure are reviewed.
More Related Videos
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
07:24A Surgical Method for Subvalvular Structure Intervention Through a Transaortic Approach in Normal Bama Pigs
Published on: March 13, 2026
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Peripheral Artery Disease III: Interprofessional Care
